Gent – Belgium, 6 February 2026

GenLumina presented the last mile in precision oncology; our approach to precision cancer treatment. It was exciting to exchange perspectives with others working on targeting therapies that recognize overexpressed markers on cancer cells.

What makes this approach powerful is the combination of proven targeting with a new type of light-activated payload. Our payload remains inactive and is switched on only by light, exactly at the tumor site. If not, is cleared by the body through the urine and feces.

This allows us to eliminate cancer cells, while largely sparing healthy tissue. As a result, we can address targets that were previously considered too risky due to side effects, resistance, or tumor recurrence.

We believe that controlling not only what we target, but also when and where the treatment is activated, represents the true “last mile” in precision oncology.

Many thanks to the Cancer Research Institute Gent (CRIG) for organizing such a well-run and engaging partnering event, and for creating a setting that truly encourages dialogue between academia and industry.